Philip D. Ross

TL;DR: It is concluded that history of prior fracture at any site is an important risk factor for future fractures and patients with a history of Prior fracture should receive further evaluation for osteoporosis and fracture risk.

TL;DR: Combining information about bone mass and prevalent fracture appears to be better for predicting new fractures than either variable alone and Physicians can use these risk factors to identify patients at greatest risk for new fractures.

TL;DR: A prospective, two-year, double-blind, placebo-controlled, multicenter study in 429 women who had one to four vertebral compression fractures plus radiographic evidence of osteopenia to determine the effects of etidronate in the treatment of postmenopausal osteoporosis.

TL;DR: An accurate assessment of the risk of fractures associated with osteoporosis and of their impact on quality of life is essential if appropriate and cost-effective interventions are to be designed for different populations.

TL;DR: A meta-analysis of all randomized, placebo-controlled trials of antiresorptive agents conducted in postmenopausal women with osteoporosis demonstrated that larger increases in BMD at both the spine and hip and larger reductions in both formation and resorption BCM are associated with greater reductions in the risk of nonvertebral fractures.